In the randomized phase II trial, researchers evaluated Elenagen, a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1—administered in combination with the standard chemotherapy gemcitabine in women with PROC and elevated CA-125.
Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.
